Personal genomic testing as part of the complete breast cancer risk assessment: A case report

Journal of Genetic Counseling

Volumn 21, Issue 5, 2012, Pages 638-644

  Riordan, Sara ^a   Rodriguez, David F ^b   Kieran, Shannon ^a  

^a Navigenics Inc   (United States)

^b Sandy Springs Internal Medicine PC   (United States)

Author keywords

Breast cancer; Case report; Genome scan; Genomics; Personal genomic testing; Personalized medicine; Risk assessment; SNP

Indexed keywords

ARTICLE; BREAST TUMOR; FEMALE; GENETICS; HUMAN; HUMAN GENOME; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; FEMALE; GENOME, HUMAN; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT;

EID: 84867396512     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-012-9506-x     Document Type: Article

References (40)

1. Ahmed, S., Thomas, G., Ghoussaini, M., Healey, C. S., Humphreys, M. K., Platte, R., et al. (2009). Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 41, 585-590.
2. American Society of Breast Surgeons. (2006). BRCA genetic testing for patients with and without breast cancer. Retrieved June 29, 2011, from http://www.breastsurgeons.org/statements/PDF-Statements/BRCA-Testing.pdf.
3. Antoniou, A. C., Sinilnikova, O. M.,McGuffog,L., Healey, S.,Nevanlinna, H., Heikkinen, T., et al. (2009). Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 18, 4442-4456.
4. Antoniou, A. C., Spurdle, A. B., Sinilnikova, O. M., Healey, S., Pooley, K. A., Schmutzler, R. K., et al. (2008). Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. American Journal of Human Genetics, 82, 937-948.
5. Bloss, C. S., Schork, N. J., & Topol, E. J. (2011). Effect of direct-toconsumer genomewide profiling to assess disease risk. New England Journal of Medicine, 364, 524-534.
6. Breast Cancer Association Consortium. (2006). Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. Journal of the National Cancer Institute, 98, 1382-1396.
7. Campeau, P. M., Foulkes, W. D., & Tischkowitz, M. D. (2008). Hereditary breast cancer: new genetic developments, new therapeutic avenues. Human Genetics, 124, 31-42.
8. Cox, A., Dunning, A. M., Garcia-Closas, M., Balasubramanian, S., Reed, M. W., Pooley, K. A., et al. (2007). A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics, 39, 352-358.
9. Easton, D. F., Pooley, K. A., Dunning, A.M., Pharoah, P. D., Thompson, D., Ballinger, D. G., et al. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087- 1093.
10. Ford, D., Easton, D. F., Bishop, D. T., Narod, S. A., & Goldgar, D. E. (1994). Lancet, 343, 692-695.
11. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics, 62, 676-689.
12. Gail, M. H., & Benichou, J. (1994). Validation studies on a model for breast cancer risk. Journal of the National Cancer Institute, 86, 573-575.
13. Garcia-Closas, M., & Chanock, S. (2008). Genetic susceptibility loci for breast cancer by estrogen receptor (ER) status. Clinical Cancer Research, 14, 8000-8009.
14. Garcia-Closas, M., Hall, P., Nevanlinna, H., Pooley, K., Morrison, J., Richesson, D. A., et al. (2008). Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genetics, 4, e1000054.
15. Gold, B., Kirchoff, T., Stefanov, S., Lautenberger, J., Viale, A., Garber, J., et al. (2008). Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.3. Nature Genetics, 40, 703-703.
16. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25, 5287-5312.
17. James, J. J., Evan, A. J., Pinder, S. E., Gutteridge, E., Cheung, K. L., Chan, S., et al. (2003). Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features. British Journal of Cancer, 89, 660-665.
18. Jatoi, I., & Proschan, M. A. (2005). Randomized trials of breastconserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. American Journal of Clinical Oncology, 28, 289-294.
19. Klinge, C. M., Blankenship, K. A., Risinger, K. E., Bhatnagar, S., Noisin, E. L., Sumanasekera, W. K., et al. (2005). Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. Journal of Biological Chemistry, 280, 7460-7468.
20. Medco Health Solutions. (2009). National Pharmacogenomics Physician Survey: Who are the physicians adopting pharmacogenomics and how does knowledge impact adoption? Medco Clinical Research Brief. Retrieved December 5, 2011 from www.medcoresearch.com.
21. Moffa, A. B., & Ethier, S. P. (2007). Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. Journal of Cellular Physiology, 210, 720-731.
22. National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology. Retrieved June 29, 2011, from http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp.
23. National Institutes of Health. (2007). Cancer Genetic Markers of Susceptibility, database of Genotypes and Phenotypes. Retrieved 2007, from http://www.ncbi.nlm.nih.gov/gap.
24. Navigenics, Inc. (2011). The science behind the Navigenics service. Retrieved June 29, 2011, from https://www.navigenics.com/static/pdf/Navigenics- TheScience.pdf.
25. Padhukasahasram, B., Halperin, E., Wessel, J., Thomas, D. J., Silver, E., Trumbower, H., et al. (2010). Presymptomatic risk assessment for chronic non-communicable diseases. PLoS One, 5, e14338.
26. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., et al. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen-receptor-positive breast cancer. Journal of Clinical Oncology, 24, 3726-3734.
27. Pharoah, P. D. P., Antoniou, A., Bobrow, M., Zimmern, R., Easton, D., & Ponder, B. A. J. (2002). Polygenic susceptibility to breast cancer and implications for prevention. Nature Genetics, 31, 33-36.
28. Pharoah, P. D. P., Antoniou, A. C., Easton, D. F., & Ponder, B. A. J. (2008). Polygenes, risk prediction, and targeted prevention of breast cancer. New England Journal of Medicine, 358, 2796- 2803.
29. Rebbeck, T. R., DeMichele, A., Tran, T. V., Panossian, S., Bunin, G., Troxel, A. B., et al. (2009). Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis, 30, 269-274.
30. Reeves, G. K., Travis, R. C., Green, J., Bull, D., Tipper, S., Baker, K., et al. (2010). Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. Journal of the American Medical Association, 304, 426-434.
31. Ries, L. A. G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B. A., Feuer, et al. (2006). SEER Cancer Statistics Review. 1975-2003, National Cancer Institute. Retrieved 2007, from http://seer.cancer.gov/csr/1975-2003.
32. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57, 75-89.
33. Smid, M., Wang, Y., Klijn, J. G., Sieuwerts, A. M., Zhang, Y., Atkins, D., et al. (2006). Genes associated with breast cancer metastatic to bone. Journal of Clinical Oncology, 24, 2261-2267.
34. Stacey, S. N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J., Gudjonsson, S. A., et al. (2007). Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptorpositive breast cancer. Nature Genetics, 39, 865-869.
35. Stacey, S. N., Manolescu, A., Sulem, P., Thorlacius, S., Gudjonsson, S. A., Jonsson, G. F., et al. (2008). Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positiv breast cancer. Nature Genetics, 40, 703-706.
36. Thomas, G., Jacobs, K. B., Kraft, P., Yeager, M., Wacholder, S., Cox, D. G., et al. (2009). A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics, 41, 579-584.
37. Tuttle, T. M., Habermann, E. B., Grund, E. H., Morris, T. J., & Virnig, B. A. (2007). Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. Journal of Clinical Oncology, 25, 5203-5209.
38. Wacholder, S., Hartge, P., Prentice, R., Garcia-Closas, M., Feigelson, H. S., Diver,W. R., et al. (2010). Performance of common genetic variants in breast-cancer risk models. New England Journal of Medicine, 362, 986-993.
39. Willems, P. J. (2007). Susceptibility genes in breast cancer: more is less? Clinical Genetics, 72, 493-496.
40. Ziogas, D., & Roukos, D. (2009). Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Annals of Surgical Oncology, 16, 1771-1782.